Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human PD-1 / PDCD1 Protein, (HPLC-verified), low endotoxin, Fc Tag, 1mg  

Recombinant human PD-1 / PDCD1 Protein, (HPLC-verified), low endotoxin, Fc Tag, 1mg

Recombinant human PD-1 / PDCD1 Protein, Leu 25 - Gln 167, produced in human 293 cells (HEK293), HPLC-verified, low endotoxin, Fc Tag

Synonym
Recombinant Human Protein, PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-l

More details

PD1-H5257-1K

Availability: within 7 days

1 980,00 €

Background
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Source
Recombinant human PD-1 / PDCD1 Protein, Fc Tag (HPLC-verified), low endotoxin (Human PD-1, Fc Tag (HPLC-verified)) Leu 25 - Gln 167 (Accession # NP_005009.2) was produced in human 293 cells (HEK293).

Molecular Characterization
Human PD-1, Fc Tag (HPLC-verified) is fused with a human IgG1 Fc tag at the C-terminus, and has a calculated MW of 42.6 kDa. The predicted N-terminus is Leu 25. The reducing (R) protein migrates as 50-66 kDa in SDS-PAGE due to glycosylation.

Endotoxin
Less than 0.1 EU per μg by the LAL method.

Purity
>95% as determined by SEC-HPLC.
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.
Contact us for customized product format or formulation.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Immobilized Human PD-L1, His Tag (Cat. No. PD1-H5229) at 5 μg/mL (100 μl/well) can bind Human PD-1, Fc Tag (HPLC-verified) (Cat. No. PD1-H5257) with a linear range of 0.05-1 μg/mL (QC tested).
Immobilized Human PD-L2, His Tag (Cat. No. PD2-H5220) at 5 μg/mL (100 μl/well) can bind Human PD-1, Fc Tag (Cat. No. PD1-H5257) with a linear range of 0.02-0.5 μg/mL (Routinely tested).

References

(1) Ishida Y., et al., 1992, EMBO J. 11 (11): 3887–95.
(2) Blank C., et al., 2007, Cancer Immunol. Immunother. 56 (5): 739–45.
(3) Agata Y., et al., 1996, Int. Immunol. 8 (5): 765–72.
(4) Freeman GJ., et al., 2000, J. Exp. Med. 192 (7): 1027–34.
(5) Latchman Y., et al., 2001, Nat. Immunol. 2 (3): 261–8.
(6) Yamazaki T., et al., 2002, J. Immunol. 169 (10): 5538–45. (HEK293)

The following products could also be interesting for you: